Laura Shawver, Director at ARS Pharmaceuticals, Inc. (SPRY), sold 90,008 shares at $7.01 ($633K) on 2023-08-03, disclosed to the SEC on 2023-08-07.
Scheduled sale ($633k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.01 | 26,107 | $183K | 28.9% |
| 2 | $7.01 | 26,107 | $183K | 28.9% |
| 3 | $7.06 | 18,897 | $133K | 21.1% |
| 4 | $7.06 | 18,897 | $133K | 21.1% |
| Total | $7.03 avg | 90,008 | $633K | 100% |
| Filing → |
| SPRY | SELL | 2025-02-04 | $616K | — | Filing → |
| SPRY | SELL | 2025-01-07 | $555K | — | Filing → |
| SPRY | SELL | 2024-12-04 | $5.2M | — | Filing → |